Role of Curcumin in Prevention and Treatment of Colorectal Cancer: The Mechanisms

Document Type : Review Article

Authors

1 PhD Student, Department of Medical Physiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

2 Assistant Professor, Department of Medical Biochemistry, School of Medicine AND Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

3 Assistant Professor, Department of Modern Sciences and Technologies, School of Medicine AND Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

4 Professor, Department of Medical Physiology, School of Medicine AND Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

Colorectal cancer is the fourth common cancer and third cause of death due to cancer in the world. Chemotherapy plus surgery are the routine methods in treatment of colorectal cancer. Cytotoxic drugs such as 5-fluorouracil, ograliplatin, and leukoverin in treating colorectal cancer have several side effects for patients. On the other hand, finding new components to improve drug responsiveness, reduce drug dosage and therefore, reduce side effects of chemotherapy are important. Curcumin is a substance of plant origin with antioxidative, anti-inflammatory, and antibacterial properties. In addition, it has antitumor effects in preclinical, and phases I and II clinical studies in various cancers such as prostate, breast, colon, and pancreas. The results of these studies indicated the efficacy, more tolerance among patients, and improving the quality of life. In this article, we reviewed the role of curcumin in colorectal cancer and the involved mechanisms.

Keywords

References

  1. Burt RW, Barthel JS, Dunn KB, David DS, Drelichman E, Ford JM, et al. NCCN clinical practice guidelines in oncology. Colorectal cancer screening. J Natl Compr Canc Netw 2010; 8(1): 8-61.
  2. Foo W, Young JM, Solomon MJ, Wright CM. Family history? The forgotten question in high-risk colorectal cancer patients. Colorectal Dis 2009; 11(5): 450-5.
  3. Temraz S, Mukherji D, Shamseddine A. Potential targets for colorectal cancer prevention. Int J Mol Sci 2013; 14(9): 17279-303.
  4. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 2014; 64(4): 252-71.
  5. Park JM, Lee HJ, Yoo JH, Ko WJ, Cho JY, Hahm KB. Overview of gastrointestinal cancer prevention in Asia. Best Pract Res Clin Gastroenterol 2015; 29(6): 855-67.
  6. Shanmugam MK, Rane G, Kanchi MM, Arfuso F, Chinnathambi A, Zayed ME, et al. The multifaceted role of curcumin in cancer prevention and treatment. Molecules 2015; 20(2): 2728-69.
  7. Rafiemanesh H, Pakzad R, Abedi M, Kor Y, Moludi J, Towhidi F, et al. Colorectal cancer in Iran: Epidemiology and morphology trends. EXCLI J 2016; 15: 738-44.
  8. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010; 19(8): 1893-907.
  9. Hoseini S, Moaddabshoar L, Hemati S, Mohammadianpanah M. An overview of clinical and pathological characteristics and survival rate of colorectal cancer in Iran. Ann Colorectal Res 2014; 2(1): 1-8.
  10. Ganesh B, Talole SD, Dikshit R. A case-control study on diet and colorectal cancer from Mumbai, India. Cancer Epidemiol 2009; 33(3-4): 189-93.
  11. Cress RD, Morris C, Ellison GL, Goodman MT. Secular changes in colorectal cancer incidence by subsite, stage at diagnosis, and race/ethnicity, 1992-2001. Cancer 2006; 107(5 Suppl): 1142-52.
  12. Abdifard E, Amini S, Bab S, Masroor N, Khachian A, Heidari M. Incidence trends of colorectal cancer in Iran during 2000-2009: A population-based study. Med J Islam Repub Iran 2016; 30: 382.
  13. Haggar FA, Boushey RP. Colorectal cancer epidemiology: Incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg 2009; 22(4): 191-7.
  14. Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JM, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010; 375(9726): 1624-33.
  15. Moghimi-Dehkordi B, Safaee A, Zali MR. Prognostic factors in 1,138 Iranian colorectal cancer patients. Int J Colorectal Dis 2008; 23(7): 683-8.
  16. Kong CK, Roslani AC, Law CW, Law SC, Arumugam K. Impact of socio-economic class on colorectal cancer patient outcomes in Kuala Lumpur and Kuching, Malaysia. Asian Pac J Cancer Prev 2010; 11(4): 969-74.
  17. Ciccolallo L, Capocaccia R, Coleman MP, Berrino F, Coebergh JW, Damhuis RA, et al. Survival differences between European and US patients with colorectal cancer: role of stage at diagnosis and surgery. Gut 2005; 54(2): 268-73.
  18. Jordan BC, Mock CD, Thilagavathi R, Selvam C. Molecular mechanisms of curcumin and its semisynthetic analogues in prostate cancer prevention and treatment. Life Sci 2016; 152: 135-44.
  19. Qadir MI, Naqvi ST, Muhammad SA. Curcumin: A Polyphenol with molecular targets for cancer control. Asian Pac J Cancer Prev 2016; 17(6): 2735-9.
  20. Hosseini M, Hassanian SM, Mohammadzadeh E, ShahidSales S, Maftouh M, Fayazbakhsh H, et al. Therapeutic potential of curcumin in treatment of pancreatic cancer: current status and future perspectives. J Cell Biochem 2017; 118(7): 1634-8.
  21. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8(12): 915-28.
  22. Yang YL, Li XM. The IAP family: Endogenous caspase inhibitors with multiple biological activities. Cell Res 2000; 10(3): 169-77.
  23. Guo LD, Jiao ZX, Song Y, Teng WH, Liu Z, Liu JZ. Study on functions and mechanism of curcumin in inducing colorectal carcinoma cells LoVo apoptosis. Zhongguo Zhong Yao Za Zhi 2013; 38(13): 2191-6. [In Chinese].
  24. Mohanty C, Sahoo SK. The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation. Biomaterials 2010; 31(25): 6597-611.
  25. Singer II, Kawka DW, Schloemann S, Tessner T, Riehl T, Stenson WF. Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology 1998; 115(2): 297-306.
  26. Li L, Aggarwal BB, Shishodia S, Abbruzzese J, Kurzrock R. Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer 2004; 101(10): 2351-62.
  27. Han SS, Chung ST, Robertson DA, Ranjan D, Bondada S. Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, c-myc, bcl-XL, NF-kappa B, and p53. Clin Immunol 1999; 93(2): 152-61.
  28. He ZY, Shi CB, Wen H, Li FL, Wang BL, Wang J. Upregulation of p53 expression in patients with colorectal cancer by administration of curcumin. Cancer Invest 2011; 29(3): 208-13.
  29. Roy S, Yu Y, Padhye SB, Sarkar FH, Majumdar AP. Difluorinated-curcumin (CDF) restores PTEN expression in colon cancer cells by down-regulating miR-21. PLoS One 2013; 8(7): e68543.
  30. Qiao L, Wong BC. Targeting apoptosis as an approach for gastrointestinal cancer therapy. Drug Resist Updat 2009; 12(3): 55-64.
  31. Patel BB, Gupta D, Elliott AA, Sengupta V, Yu Y, Majumdar AP. Curcumin targets FOLFOX-surviving colon cancer cells via inhibition of EGFRs and IGF-1R. Anticancer Res 2010; 30(2): 319-25.
  32. Liu LB, Duan CN, Ma ZY, Xu G. Curcumin inhibited rat colorectal carcinogenesis by activating PPAR-gamma: an experimental study. Zhongguo Zhong Xi Yi Jie He Za Zhi 2015; 35(4): 471-5. [In Chinese].
  33. Li B, Xu W, Luo C, Gozal D, Liu R. VEGF-induced activation of the PI3-K/Akt pathway reduces mutant SOD1-mediated motor neuron cell death. Brain Res Mol Brain Res 2003; 111(1-2): 155-64.
  34. Slupianek A, Nieborowska-Skorska M, Hoser G, Morrione A, Majewski M, Xue L, et al. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res 2001; 61(5): 2194-9.
  35. Johnson SM, Gulhati P, Arrieta I, Wang X, Uchida T, Gao T, et al. Curcumin inhibits proliferation of colorectal carcinoma by modulating Akt/mTOR signaling. Anticancer Res 2009; 29(8): 3185-90.
  36. Yan C, Jamaluddin MS, Aggarwal B, Myers J, Boyd DD. Gene expression profiling identifies activating transcription factor 3 as a novel contributor to the proapoptotic effect of curcumin. Mol Cancer Ther 2005; 4(2): 233-41.
  37. Subramaniam A, Shanmugam MK, Perumal E, Li F, Nachiyappan A, Dai X, et al. Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma. Biochim Biophys Acta 2013; 1835(1): 46-60.
  38. Rajitha B, Nagaraju GP, Shaib WL, Alese OB, Snyder JP, Shoji M, et al. Novel synthetic curcumin analogs as potent antiangiogenic agents in colorectal cancer. Mol Carcinog 2017; 56(1): 288-99.
  39. Roy HK, Olusola BF, Clemens DL, Karolski WJ, Ratashak A, Lynch HT, et al. AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis 2002; 23(1): 201-5.
  40. Zhang J, Feng Z, Wang C, Zhou H, Liu W, Kanchana K, et al. Curcumin derivative WZ35 efficiently suppresses colon cancer progression through inducing ROS production and ER stress-dependent apoptosis. Am J Cancer Res 2017; 7(2): 275-88.
  41. Szarka CE, Pfeiffer GR, Hum ST, Everley LC, Balshem AM, Moore DF, et al. Glutathione S-transferase activity and glutathione S-transferase mu expression in subjects with risk for colorectal cancer. Cancer Res 1995; 55(13): 2789-93.
  42. Marnett LJ. Lipid peroxidation-DNA damage by malondialdehyde. Mutat Res 1999; 424(1-2): 83-95.
  43. Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, et al. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 2001; 7(7): 1894-900.
  44. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001; 21(4B): 2895-900.
  45. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 2004; 10(20): 6847-54.
  46. Garcea G, Berry DP, Jones DJ, Singh R, Dennison AR, Farmer PB, et al. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 2005; 14(1): 120-5.
  47. Carroll RE, Benya RV, Turgeon DK, Vareed S, Neuman M, Rodriguez L, et al. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res (Phila) 2011; 4(3): 354-64.
  48. Irving GR, Howells LM, Sale S, Kralj-Hans I, Atkin WS, Clark SK, et al. Prolonged biologically active colonic tissue levels of curcumin achieved after oral administration--a clinical pilot study including assessment of patient acceptability. Cancer Prev Res (Phila) 2013; 6(2): 119-28.
Journal of Isfahan Medical School
Volume 35, Issue 441 - Serial Number 441
July and August 2017
Pages 969-977

Files

History

  • Receive Date: 18 April 2017
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics